Investing

argenx : ARGX

ARGX

Stock Data

$869.10

$6.20 (0.71%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Argenx SE is a biotechnology firm based in Amsterdam, focusing on developing treatments for autoimmune diseases. Its flagship product, efgartigimod, aims to help patients with conditions like myasthenia gravis and pemphigus vulgaris. Beyond efgartigimod, Argenx is working on a range of therapies targeting severe autoimmune diseases and airway inflammation. The company collaborates with global partners, including AbbVie and Zai Lab, to advance its research and bring innovative therapies to market.

Latest Activity

ARGXArgenx

Q2 2026

Jul 23, 8:21am ET

EPS

$7.32

est $6.19+18.2%

Revenue

$1.52B

est $1.43B+5.7%

VYVGART's expanded label is working: argenx grew revenue 60% to $1.52B and beat EPS by 18% as its star neurology franchise locks in coverage for 55% of U.S. commercial lives across all adult myasthenia gravis serotypes, with Japan sales alone up 117% year-over-year.

ShareRead more

All argenx Articles

1 Article

Lee Jackson | Dec 18, 2025 at 7:50 AM EST

Here Are Thursday’s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More

Pre-Market Stock Futures: Futures are trading higher on Thursday as we grind closer to the Christmas holiday, which is just…